M&A Deal Summary

Viatris Acquires Meda

On February 10, 2016, Viatris acquired life science company Meda for 9.9B USD

Acquisition Highlights
  • This is Viatris’ 6th transaction in the Life Science sector.
  • This is Viatris’ largest (disclosed) transaction.
  • This is Viatris’ 1st transaction in Sweden.

M&A Deal Summary
Date 2016-02-10
Target Meda
Sector Life Science
Buyer(s) Viatris
Deal Type Add-on Acquisition
Deal Value 9.9B USD

Target

Meda

Solna, Sweden
website
Meda is an operator of an international specialty pharma company that is fully represented in Europe and the US through its own sales organizations in more than 50 countries. Meda’s products are sold in about 120 countries, and where it lacks a sales organization, it markets and sells its products via agents and other pharmaceutical companies. Meda has a diversified geographic footprint with approximately 62 percent of Meda's sales generated in Western Europe (the largest countries being Italy, Germany, France, and Sweden), 19 percent in Emerging Markets (driven by China, Russia, the Middle East, and Thailand) and 17 percent in the U.S. Meda has a network of seven manufacturing facilities in Europe, the U.S. and India. Meda is based in Solna, Sweden.

Search 192,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Viatris

Canonsburg, Pennsylvania, United States

website

Category Company
Founded 1961
Sector Life Science
Employees40,000
Revenue 17.9B USD (2021)
DESCRIPTION

Viatris is a generic and specialty pharmaceutical company. Viatris offers the industry's broadest and highest quality product portfolios, a robust product pipeline, and a global commercial footprint through operations in more than 90 countries. Viatris was founded in 1961 and is based in Canonsburg, Pennsylvania.

DEAL STATS #
Overall 9 of 13
Sector (Life Science) 6 of 10
Type (Add-on Acquisition) 4 of 4
Country (Sweden) 1 of 1
Year (2016) 1 of 2
Size (of disclosed) 1 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-02-27 Abbott - Non-U.S. Developed Markets Specialty and Branded Generics

United States

Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business.

Buy $5.3B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-05-13 Renaissance Acquisition - Specialty and Generics Business

Quebec, Canada

Renaissance Acquisition - Specialty and Generics Business comprises portfolio of specialty brands and generic products in the dermatology space, as well as a deep pipeline of complex topical generics and brands in active development. The Business has two high-quality manufacturing sites with capabilities and capacity in creams, ointments, aerosols/foams, gels, suspensions, liquids and suppositories that are complementary to Mylan's existing capabilities.

Buy $1.0B
Mergr

Product

Company

Legal